Immune checkpoint blockade (ICB) has demonstrated promise in patients with malignant tumors, particularly antibodies targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), has demonstrated promise as a representative immunotherapy (2). Here, CTLA4 is linked to cancer.